<DOC>
	<DOCNO>NCT00001052</DOCNO>
	<brief_summary>To extend evaluation safety immunogenicity MN recombinant soluble gp120/HIV-1 ( MN rsgp120/HIV-1 ) combination QS21 without alum two different vaccination schedule . Recent animal study indicate immunize MN rsgp120/HIV-1 combination QS21 0 , 1 , 2 month schedule result rapid rise bind neutralize antibody response 0 , 1 , 6 month schedule . Such effect may particularly desirable vaccine delivery . This study compare two delivery schedule use unadjuvanted vaccine formulation rsgp120/HIV-1 without addition alum .</brief_summary>
	<brief_title>A Phase I , Multicenter , Randomized , Double-Blind , Placebo-Controlled HIV-1 Vaccine Trial Evaluate Safety Immunogenicity MN Recombinant Soluble gp120/HIV-1 ( rsgp120/HIV-1 ) ( Genentech ) Combination With QS21 Adjuvant and/or Alum Healthy Adults</brief_title>
	<detailed_description>Recent animal study indicate immunize MN rsgp120/HIV-1 combination QS21 0 , 1 , 2 month schedule result rapid rise bind neutralize antibody response 0 , 1 , 6 month schedule . Such effect may particularly desirable vaccine delivery . This study compare two delivery schedule use unadjuvanted vaccine formulation rsgp120/HIV-1 without addition alum . Healthy volunteer ( 20 per group ) receive MN rsgp120/HIV-1 ( 300 0 mcg ) combination QS21 ( 100 mcg ) , either without alum , 0 , 1 , 2 month 0 , 1 , 6 month . For vaccination schedule , additional five volunteer receive vehicle alum . The 0 mcg antigen group include primarily negative control . Subjects may contact follow-up health status twice yearly least 5 year .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Inclusion Criteria Subjects must : Normal history physical exam . HIV negative ELISA within 8 week immunization . Absolute CD4 count &gt; = 400 cells/mm3 . Normal urine dipstick esterase nitrite . Exclusion Criteria Coexisting Condition : Subjects follow symptoms condition exclude : Hepatitis B surface antigen . Medical psychiatric condition ( recent suicidal ideation present psychosis ) preclude compliance . Occupational responsibility preclude compliance . Active syphilis . NOTE : Subjects serology document false positive due remote ( &gt; 6 month ) treat infection eligible . Active tuberculosis . NOTE : Subjects positive PPD normal chest xray show evidence TB require isoniazid therapy eligible . Subjects follow prior condition exclude : History immunodeficiency , autoimmune disease , use immunosuppressive medication . History anaphylaxis serious adverse reaction vaccine . History allergy thimerosal . History serious allergic reaction substance , require hospitalization emergent medical care ( e.g. , StevensJohnson syndrome , bronchospasm , hypotension ) . Prior psychiatric condition ( history suicide attempt past psychosis ) preclude compliance . History cancer unless surgical excision consider achieved cure . Prior Medication : Excluded : Live attenuate vaccine within 60 day prior study entry . ( NOTE : Medically indicate subunit kill vaccine , influenza pneumococcal , allow give least 2 week prior HIV immunization . ) Experimental agent within 30 day prior study entry . Prior HIV vaccine . Prior Treatment : Excluded : Receipt blood product immunoglobulin within past 6 month . Risk Behavior : Subjects NOT excluded basis HIV risk behavior , AVOIDANCE activity may expose subject HIV ( e.g. , unprotected sex needle share ) STRONGLY RECOMMENDED .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>